Arena, Orexigen in spotlight; drug indexes dip
September 16, 2010 at 11:58 AM EDT
Rivals Orexigen Therapeutics and Arena Pharmaceuticals are in the spotlight as a Food and Drug Administration advisory panel convenes to consider whether to recommend Arena’s diet-drug lorcaserin for approval.